FindTrial
Sign In

Efficacy and safety of low-dose rituximab in the treatment of membranous nephropathy

Efficacy and safety of low-dose rituximab in the treatment of membranous nephropathy

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200057381
Enrollment
Unknown
Registered
2022-03-10
Start date
2022-03-01
Completion date
Unknown
Last updated
2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

membranous nephropathy

Interventions

rituximab group:rituximab
control:hormone combined with cyclophosphamide

Sponsors

Peking University Third Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Clinical diagnosis of nephrotic syndrome; 2. Renal biopsy for diagnosis of IMN; 3. Blood PLA2R antibody>20IU/ml; 4. Age: 18-80 (inclusive), regardless of gender; 5.eGFR>30 ml/min.

Exclusion criteria

Exclusion criteria: 1. Renal pathology indicates that in addition to IMN, there are also other kidney diseases, such as diabetes nephropathy; 2. Secondary IMN, such as systemic lupus erythematosus, chronic hepatitis B, tuberculosis, tumor, etc.

Design outcomes

Primary

MeasureTime frame
nephrotic syndrome outcome;renal function;—

Secondary

MeasureTime frame
complications;—

Countries

China

Contacts

Public ContactDanxia Zheng

Peking University Third Hospital

dxheng@sina.com+86 13522758603

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 9, 2026